4//SEC Filing
Gall Matthew 4
Accession 0001193125-25-262831
CIK 0001754068other
Filed
Nov 2, 7:00 PM ET
Accepted
Nov 3, 5:25 PM ET
Size
5.6 KB
Accession
0001193125-25-262831
Insider Transaction Report
Form 4
Gall Matthew
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-11-03+235,000→ 235,000 totalExercise: $4.99Exp: 2035-11-02→ Common Stock (235,000 underlying)
Footnotes (1)
- [F1]The option was granted on November 3, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on November 3, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
Documents
Issuer
Kalaris Therapeutics, Inc.
CIK 0001754068
Entity typeother
Related Parties
1- filerCIK 0001816194
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 7:00 PM ET
- Accepted
- Nov 3, 5:25 PM ET
- Size
- 5.6 KB